<DOC>
	<DOCNO>NCT00696579</DOCNO>
	<brief_summary>A significant number patient high risk superficial bladder cancer progression invasive disease . No consensus exist regard optimal treatment decrease recurrence progression rate . The aim research evaluate safety , tolerability efficacy adjuvant intravesical gemcitabine vs. BCG treatment high-risk superficial bladder cancer</brief_summary>
	<brief_title>Bacillus Calmette Guerin ( BCG ) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer</brief_title>
	<detailed_description>This prospective , randomize study conduct 2004 2006 single tertiary urban teach University Urological Department regard sixty-four patient high-risk superficial bladder cancer ( pT1 , and/or G3 and/or CIS ) , assign intervention ( gemcitabine BCG ) use random allocation 1:1 . Group A , 32 patient , treated weekly ( 6 weekly instillation ) BCG dose 5 x 108 CFU maintenance therapy 3-6-12-18-24-30-36 month ; Group B , 32 patient , receive gemcitabine 2 gr/instillation weekly basis ( 6 weekly instillation ) , follow maintenance therapy 3-6-12-18-24-30-36 month .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Primary diagnosis high risk superficial bladder cancer accord EAU guideline ( http : //www.eortc.be/tools/bladdercalculator/ ) , Having never treat intravesical chemotherapeutic agent , And consent participate study Concomitant tumours ; Urinary tract infection ( UTI ) ; Altered function liver , kidney and/or bone marrow ; Major cardiovascular disease ; Life expectancy less 1 year ; Intravesical chemotherapy previous 3 month immunotherapy previous 6 month ; Systemic chemotherapy pelvic radiotherapy prior TURB , condition judgment investigator would interfere subject 's ability provide inform consent , comply study instruction , place subject increase risk , might confound interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>BCG</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Intravesical</keyword>
	<keyword>Therapy</keyword>
	<keyword>Superficial</keyword>
	<keyword>Transitional</keyword>
	<keyword>Cell carcinoma</keyword>
</DOC>